Literatur

¹. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf]
². Bodey GP e t al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
³. Aapro MS et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
⁴. Lyman GH e t al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117: 1917-27.
⁵. Kuderer NM et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-66.
⁶. Kuderer NM et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007; 25: 3158-67.
⁷. Lyman GH et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. J Clin Oncol 2010; 28: 2914-24.
⁸. Lyman GH et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; 24: 2475-84.
⁹. Garcia-Carbonero R et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-38.
¹⁰. Crawford J. NCCN® Practice Guidelines in Oncology - v.2.2014; Myeloid Growth Factors. In: National Comprehensive Cancer Network. Edited by NCCN; 2014.
¹¹. Smith TJ et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-205.
¹². Bennett CL et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013; 368: 1131-9.
¹³. Flowers CR et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794-810.
¹⁴. Vehreschild JJ et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy - evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol 2014; 25: 1709-18.
¹⁵. Dale DC et al. Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003; 1: 440-54.
¹⁶. Freedman O et al. Filling in the gaps: Reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Support Care Cancer 2011; 19: 315-22.
¹⁷. Lyman GH et al. Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. J Clin Oncol 2008; 26 (15S): 350s (ASCO 2008, Abstract #6552).
¹⁸. Cooper KL et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer 2011; 11: 404.
¹⁹. Pfeil AM et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: A systematic review. Support Care Cancer 2015; 23: 525-45.
²⁰. Pinto L et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: A meta-analysis of randomized controlled trials. Curr Med Res Opin 2007; 23: 2283-95.
²¹. Naeim A et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: A retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013; 13: 11.
²². Pujol JL et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300-8.
²³. von Pawel J et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-67.
²⁴. Schmittel A et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011; 22: 1798-804.
²⁵. Pujol JL et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16: 602-10.
²⁶. Fossella F et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003; 21: 3016-24.
²⁷. Douillard JY et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
²⁸. Langer CJ et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-70.
²⁹. Hanna N et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
³⁰. Minckwitz G von et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008; 19: 292-8.
³¹. Martin M et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-13.
³². Burnell M et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2010; 28: 77-82.
³³. Roche H et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol 2006; 24: 5664-71.
³⁴. Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-83.
³⁵. Sparano JA et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-71.
³⁶. Pfreundschuh M et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008; 19: 545-52.
³⁷. Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
³⁸. Corazzelli G et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64: 907-16.
³⁹. Schrijvers D et al. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21: v244-v247.
⁴⁰. Salpeter SR e t al. Impact of more restrictive blood transfusion strategies on clinical outcomes: A meta-analysis and systematic review. Am J Med 2014; 127: 124-31
⁴¹. Carson JL. Blood transfusion and risk of infection: New convincing evidence. J Am Med Ass 2014; 311: 1293-4.
⁴². Rohde JM et al. Health care-associated infection after red blood cell transfusion: A systematic review and meta-analysis. J Am Med Ass 2014; 311: 1317-26.
⁴³. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database System Rev 2006; 1: Art. No.: CD005033(1):CD005033.
⁴⁴. Carson JL et al. Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion. J Am Med Ass 2013; 309: 83-4.
⁴⁵. Aapro M, Link H. Update on EORTC guidelines and anemia management with erythropoiesis stimulating agents (ESAs). Oncologist 2008; 13 (Suppl.. 3): 33-6.
⁴⁶. Cella D et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 2004; 15: 979-86.
⁴⁷. Aapro M et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: A meta-analysis. Ann Oncol 2014, Dec 26 [Epub ahead of print, pii: mdu579].
⁴⁸. Bohlius J et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009; 373: 1532-42.
⁴⁹. Gafter-Gvili A et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013; 52: 18-29.
⁵⁰. Kaufman PA et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology 2015; 33: 594-601.